What is Alfie?
Alfie Health operates at the intersection of artificial intelligence and metabolic medicine. Its core offering, the ObesityRx platform, provides healthcare providers with actionable insights to manage patients with complex metabolic conditions. By integrating evidence-based care models with proprietary technology, Alfie facilitates a more personalized approach to obesity management. Following its acquisition by knownwell, the company is poised to expand its reach, embedding its AI-powered diagnostic and treatment tools into a broader clinical ecosystem designed to improve long-term health outcomes for individuals struggling with metabolic disorders.
How much funding has Alfie raised?
Alfie has raised a total of $2.1M across 1 funding round:
Other Financing Round
$2.1M
Other Financing Round (2023): $2.1M with participation from Nina Capital, Goodwater Capital, Phoenix Fund, and Y Combinator
Key Investors in Alfie
Nina Capital
A specialized venture capital firm focused on investing in health technology companies at the pre-seed and seed stages, providing capital to founders aiming to transform healthcare through information technology.
Goodwater Capital
A consumer tech investment firm that empowers exceptional entrepreneurs to create positive change, focusing on innovative companies across sectors including financial services, retail, and healthcare.
Phoenix Fund
An organization that empowers Harvard Business School investors to support and invest in startups from the Harvard community, fostering entrepreneurship and innovation.
What's next for Alfie?
With the integration into knownwell, the strategic focus for Alfie shifts toward operational synergy and the widespread deployment of its metabolic management tools. The company is expected to leverage its recent capital to refine its algorithmic capabilities, ensuring that its clinical decision support systems remain at the forefront of the industry. As the healthcare sector continues to prioritize value-based care, Alfie's ability to demonstrate measurable improvements in patient health will be critical. Future growth will likely center on expanding the ObesityRx platform's utility across diverse patient populations and deepening its impact within the broader digital health market.
See full Alfie company page
